CancerNCT06877884
A Prospective Registry to Enable Collection of Standardized Routine Care Oncology Patient Data
An observational study of Cancer, run by N-Power Medicine at 7 sites in United States.
Trial summary
This is an observational registry for patients at participating oncology centers. The data collection includes but is not limited to baseline variables, treatments given and outcome data. Patient surveys are also included. Read more about this study
- Who is it for?
- Ages 18 to 120 yearsHealthy volunteers can take part
- Conditions the study is for
- Cancer
- How many people
- 20,000 participants
- Where
- 7 sitesUnited States
- Study dates
- 1 Aug 2022to Jan 2099
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 120 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: All patients at oncology sites participating in the registry.
Who may be able to join
- Be a patient at a site (oncology) participating in the Registry Be at least 18 years old Be able and willing to provide signed informed consent
Who cannot join
- Prisoners/imprisonment at time of screening for eligibility Patients who cannot consent without utilization of a legally authorized representative
Trial locations and contacts
7 sites in 1 country. Contact the study team or a site near you to ask about taking part.
7 sites in 1 country
United States7 sites, 7 recruiting
- Recruiting
New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico, 87109
research@nmohc.com
Registry Help Line, 833-4NPM-REG, support@npowermedicine.com
- Recruiting
Bayhealth Cancer Center-Kent
Dover, Delaware, 19901
Stephanie McClellan, 814-744-7995, Clinical_trials@bayhealth.org
Iftekar Khan, MD
- Recruiting
Northwest Oncology & Hematology
Elk Grove Village, Illinois, 60007
Nowsheen Azeemuddin, 847-437-3312, nowsheena@northwestoncology.com
Registry Help Line, 833-4NPM-REG, support@npowermedicine.com
- Recruiting
Oncology Consultants, P.A.
Houston, Texas, 77030
Research Lead, 713-600-0913, support@npowermedicine.com
1-833-4NPM-REG
- Recruiting
Bayhealth Cancer Center- Sussex
Milford, Delaware, 19963
Stephanie McClellan, 302-744-7995, Clinical_trials@bayhealth.org
Iftekar Kahn, MD
- Recruiting
Pacific Cancer Care
Monterey, California, 93940
NPM Study Coordinator, 831-375-4105, support@npowermedicine.com
Registry Help Line, 833-4NPM-REG
- Recruiting
Lankenau Medical Center
Paoli, Pennsylvania, 19301
Jessica Burrell, 484-476-2649, burrellje@mlhs.org
Paul Gilman, MD
About this study
Official title: A Prospective Registry for Collecting Standardized, Routine Care Data to Characterize Patients, Treatment Patterns, Safety and Treatment Effectiveness in Adult Oncology Patients
This is an observational registry for patients at participating oncology centers. The data collection includes but is not limited to baseline variables, treatments given and outcome data. Patient surveys are also included. The aim of the study is to generate rich and standardized data for patients and to help enable more patients participate in clinical trials and contribute to research and development.
Read the detailed description
This is an observational registry for patients at participating oncology centers. The data collection includes but is not limited to baseline variables, treatments given and outcome data. Patient surveys are also included. The aim of the study is to generate rich and standardized data for patients and to help enable more patients participate in clinical trials and contribute to research and development.
- Conditions
- Cancer
- Medical subject headings
- Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Treatment Effectiveness - Time to treatment discontinuation
Effectiveness outcomes of treatments used in routine clinical care (such as for instance time to treatment discontinuation ) will be captured
Measured: This is an open-ended registry where data will be collected, analysed and presented regularly over time.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Mar 2025
- Study start1 Aug 2022
- Primary completionJan 2099 (estimated)
- Study completionJan 2099 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20,000 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- N-Power Medicine
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06877884
- Sponsor's protocol ID
- NPM-001
- Status last verified
- Oct 2025
- First submitted
- 11 Feb 2025
- Last updated
- 20 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Registry for Collecting Standardized, Routine Care Data to Characterize Patients, Treatment Patterns, Safety and Treatment Effectiveness in Adult Oncology Patients
- ClinicalTrials.gov ID
- NCT06877884
- Acronym / sponsor ID
- NPM-001
- Conditions
- Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 20,000 participants (estimated)
- Lead sponsor
- N-Power MedicineIndustry (pharma, biotech, devices)
- Study start
- 1 Aug 2022 (actual)
- Primary completion
- Jan 2099 (estimated)
- Study completion
- Jan 2099 (estimated)
- First posted
- 14 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an observational registry for patients at participating oncology centers. The data collection includes but is not limited to baseline variables, treatments given and outcome data. Patient surveys are also included. The aim of the study is to generate rich and standardized data for patients and to help enable more patients participate in clinical trials and contribute to research and development.
Detailed description
This is an observational registry for patients at participating oncology centers. The data collection includes but is not limited to baseline variables, treatments given and outcome data. Patient surveys are also included. The aim of the study is to generate rich and standardized data for patients and to help enable more patients participate in clinical trials and contribute to research and development.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 10 Years
Who may qualify
- Ages
- 18 to 120 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- All patients at oncology sites participating in the registry.
Key inclusion criteria (1 listed)
- Be a patient at a site (oncology) participating in the Registry Be at least 18 years old Be able and willing to provide signed informed consent
Key exclusion criteria (1 listed)
- Prisoners/imprisonment at time of screening for eligibility Patients who cannot consent without utilization of a legally authorized representative
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Treatment Effectiveness - Time to treatment discontinuation
Time frame: This is an open-ended registry where data will be collected, analysed and presented regularly over time.
Effectiveness outcomes of treatments used in routine clinical care (such as for instance time to treatment discontinuation ) will be captured
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by N-Power Medicine at 7 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Christer Svedman, MD (833-467-6734, support@npowermedicine.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Treatment Effectiveness - Time to treatment discontinuation (time frame: This is an open-ended registry where data will be collected, analysed and presented regularly over time.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2025.